- Home
- Equipment
- usa california
- non small cell lung cancer
Show results for
Refine by
Non Small Cell Lung Cancer Equipment Supplied In Usa California
7 equipment items found
Manufactured by:Lineage Cell Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our pluripotent cell technology using a directed differentiation method, is comprised of a population of mature dendritic cells. As the most potent type ...
Manufactured by:Biocept based inSan Diego, CALIFORNIA (USA)
This kit detects EGFR mutations in DNA derived from blood plasma or FFPE tissue sections to give insight into cancer characteristics and provide Biomarker status of tumors such as non-small cell lung ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) that is expressed in multiple solid tumors while restricted to germ line cells in normal tissues. T-Cure estimates that KK-LC-1 is expressed in 80% gastric cancer, 75% triple negative breast cancer (TNBC), 45% ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is evaluating CX-2029 in a Phase 1/2 clinical trial as monotherapy. CD71 is an excellent “internalizer,” which has the potential to efficiently deliver toxin to tumor cells. Historically, CD71 has not been widely pursued as a target given its expression on normal tissues and potential for causing toxicities. CytomX presented initial Phase 1 data at ASCO 2020 ...
Manufactured by:Guardant Health, Inc. based inRedwood City, CALIFORNIA (USA)
Our Guardant360® CDx test is FDA-approved for complete genomic testing across all solid cancers, providing doctors guideline-complete genomic results in 7 days from a simple blood draw to inform treatment decisions. A blood test does not require tissue testing, enabling more patients to benefit from the growing number of FDA-approved targeted therapies. Starting with the ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
BridgeBio is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. SHP2, encoded by the PTPN11 gene, links growth factor signaling with the downstream RAS/ERK/MAPK pathway to regulate cell growth and division. Over-activity of this pathway, often driven by distinct gene mutations, causes or contributes to many human cancers. ...
Manufactured by:MiraDx based inLos Angeles, CALIFORNIA (USA)
Although it is completely logical that inherited, germ-line genetic differences, present in all cells, including those of the immune system, will predict response and toxicity to developing immune therapies, there has been little study of the genomic areas studied by MiraDx to find such biomarkers. MiraDx discovered a panel of such mutations that predict both response and toxicity to anti-PD1 and ...